RegulatoryCompany release

FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer

F. Hoffmann-La Roche Ltd · Mon 16 Nov 2026

Roche says the US regulator has cleared giredestrant plus everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after prior endocrine therapy.

Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Wilserdly (giredestrant), an oral selective oestrogen receptor degrader (SERD), for use in combination with everolimus.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: F. Hoffmann-La Roche Ltd ↗

Article written by VigiEye from the official source (F. Hoffmann-La Roche Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →